Table of Contents Author Guidelines Submit a Manuscript
Journal of Analytical Methods in Chemistry
Volume 2018, Article ID 7370651, 7 pages
https://doi.org/10.1155/2018/7370651
Research Article

Different Spectrophotometric Methods for Simultaneous Determination of Trelagliptin and Its Acid Degradation Product

1Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, Ein Helwan, Cairo 11795, Egypt
2Pharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Shorouk City, Cairo 11837, Egypt
3The Center for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt, El-Shorouk City, Cairo 11837, Egypt
4Pharmaceutical Chemistry Department, Faculty of Pharmacy, Helwan University, Ein Helwan, Cairo 11795, Egypt

Correspondence should be addressed to Bassam M. Ayoub; ge.ude.eub@buoya.massab

Received 5 July 2017; Accepted 3 December 2017; Published 30 January 2018

Academic Editor: Krishna K. Verma

Copyright © 2018 Shereen Mowaka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Kushwaha, W. Haq, and S. B. Katti, “Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective,” Current Medicinal Chemistry, vol. 21, no. 35, pp. 4013–4045, 2014. View at Publisher · View at Google Scholar
  2. D. Stoimenis, T. Karagiannis, A. Katsoula et al., “Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis,” Expert Opinion on Pharmacotherapy, vol. 18, no. 9, pp. 843–851, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Harada and N. Inagaki, “Once-weekly DPP-4 inhibitor,” Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 73, no. 12, pp. 2096–2102, 2015. View at Google Scholar
  4. K. Kaku, “Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients,” Expert Opinion on Drug Safety, vol. 16, no. 11, pp. 1313–1322, 2017. View at Publisher · View at Google Scholar
  5. K. McKeage, “Trelagliptin: first global approval,” Drugs, vol. 75, no. 10, pp. 1161–1164, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Kaku, “First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus,” Expert Opinion on Pharmacotherapy, vol. 16, no. 16, pp. 2539–2547, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Yang, S. P. Zhan, and H. Y. Zhang, “Clinical application review of the novel once-weekly DPP-4 inhibitor trelagliptin in the treatment of type 2 diabetes,” Chinese Journal of New Drugs, vol. 26, no. 2, pp. 145–150, 2017. View at Google Scholar
  8. M. Murakami, N. Hirahara, H. Morita, and S. Sasaki, “Efficacy and safety of trelagliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor: a non-inferiority study in switching from daily DPP-4 inhibitor for the treatment of type 2 diabetes patients,” Journal of the Japan Diabetes Society, vol. 60, no. 3, pp. 222–228, 2017. View at Google Scholar
  9. C. E. Grimshaw, A. Jennings, R. Kamran et al., “Trelagliptin (syr-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (dpp-4) via a non-covalent mechanism,” PLoS One, vol. 11, no. 6, Article ID 0157509, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Hu, T. Lan, Z. Chen et al., “A rapid and sensitive UHPLC-MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 1033-1034, pp. 166–171, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. Q. Wang, X. Chen, C. Zhang et al., “Determination of the enantiomeric purity of trelagliptin by pre-column derivatization and liquid chromatography on a chiral stationary phase,” Chromatographia, vol. 78, no. 21-22, pp. 1395–1400, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Zhang, L. Sun, L. Zou et al., “Identification, characterization and HPLC quantification of process-related impurities in trelagliptin succinate bulk drug: six identified as new compounds,” Journal of Pharmaceutical and Biomedical Analysis, vol. 128, pp. 18–27, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Deng, Z. Li, J. Jiang et al., “Determination of related substances in trelagliptin succinate by RP-HPLC and identification of impurities from acid degradation by LC-MS/MS,” Chinese Journal of New Drugs, vol. 25, no. 2, pp. 226–231, 2016. View at Google Scholar
  14. International Conference on Harmonization (ICH), Q2B: Validation of Analytical Procedures: Methodology, 62, US FDA, Federal Register, Washington, DC, USA, 1997.